Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bullfrog AI Holdings, Inc. Common Stock (BFRG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BFRG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -83.98% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.22M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.64 | 52 Weeks Range 1.23 - 4.84 | Updated Date 06/29/2025 |
52 Weeks Range 1.23 - 4.84 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -78.05% | Return on Equity (TTM) -141.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10607832 | Price to Sales(TTM) 262.62 |
Enterprise Value 10607832 | Price to Sales(TTM) 262.62 | ||
Enterprise Value to Revenue 205.12 | Enterprise Value to EBITDA -12.02 | Shares Outstanding 9415520 | Shares Floating 7018332 |
Shares Outstanding 9415520 | Shares Floating 7018332 | ||
Percent Insiders 25.96 | Percent Institutions 4.5 |
Upturn AI SWOT
Bullfrog AI Holdings, Inc. Common Stock
Company Overview
History and Background
Bullfrog AI Holdings, Inc. is a company focused on leveraging artificial intelligence to transform drug development. Founded in 2016, it aims to accelerate and de-risk the drug development process through its proprietary platform.
Core Business Areas
- AI-Driven Drug Development: Development of AI and machine learning capabilities to accelerate drug discovery and reduce failure rates in clinical trials.
- biophysica platform: Proprietary platform to analyzes complex biological data sets to identify drug development insights.
- Data Analytics Services: Provide data analytics service offerings to pharmaceutical and biotechnology companies.
Leadership and Structure
The company is led by a management team with experience in biotechnology, data science, and drug development. Organizational structure includes departments for research and development, data science, and business development.
Top Products and Market Share
Key Offerings
- biophysica Platform: A proprietary platform enabling insights into drug development through complex data analysis. Data on market share is not readily available. Competitors include Schrodinger, Recursion Pharmaceuticals, and Exscientia.
- Data Analytics Services: Data analytic services for drug discovery, development, and clinical trial optimization. Data on market share is not readily available. Competitors include Certara, Phesi, and Medidata Solutions.
Market Dynamics
Industry Overview
The pharmaceutical industry is investing heavily in AI and machine learning to improve drug discovery and development efficiency. This includes drug target identification, biomarker discovery, clinical trial optimization, and personalized medicine applications.
Positioning
Bullfrog AI Holdings, Inc. is positioned as an innovative AI-driven company targeting the drug development process. Its competitive advantage lies in its proprietary biophysica platform.
Total Addressable Market (TAM)
The TAM for AI in drug discovery is estimated in the tens of billions of dollars. Bullfrog AI is positioned to capture a portion of this market by offering unique AI driven data insights.
Upturn SWOT Analysis
Strengths
- Proprietary biophysica platform
- Expertise in AI and machine learning
- Focus on drug development
- Data driven approach
Weaknesses
- Limited financial resources
- Small market presence
- Reliance on platform adoption
- Dependence on key partnerships
Opportunities
- Growing demand for AI in drug development
- Partnerships with pharmaceutical companies
- Expansion of platform capabilities
- Securing additional funding
Threats
- Competition from larger companies
- Technological advancements by competitors
- Regulatory hurdles
- Market acceptance of AI in drug development
Competitors and Market Share
Key Competitors
- SCHR
- RXRX
- EXAI
Competitive Landscape
Bullfrog AI Holdings, Inc. competes with larger, more established companies. It differentiates itself through its biophysica platform and focus on complex data analysis. However, it faces challenges in market penetration and resource constraints.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require specific financial data, which is best sourced directly from company filings.
Future Projections: Future growth projections require analyst estimates and company guidance, which may be available through financial news and analyst reports.
Recent Initiatives: Recent initiatives include platform enhancements, partnerships with pharmaceutical companies, and securing additional funding.
Summary
Bullfrog AI Holdings, Inc. is an AI-driven company focused on drug development, with a promising proprietary platform. Its strengths lie in its technology and focus. However, the company faces challenges due to its limited financial resources and competition from larger players. Its future success depends on platform adoption and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Third-party industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and competitor information are estimates and may not be precise. Financial data is not readily available and must be verified through official filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bullfrog AI Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2023-02-13 | Founder, Chairman & CEO Mr. Vininder Singh | ||
Sector Healthcare | Industry Health Information Services | Full time employees - | Website https://www.bullfrogai.com |
Full time employees - | Website https://www.bullfrogai.com | ||
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It also has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.